BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BA1302 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BA1302\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06596915-2378@assetmemo.bio
DTSTAMP:20261121T005336Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BA1302: Phase 1 readout est. (NCT06596915)
DESCRIPTION:BA1302\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Safety a
 nd Efficacy of BA1302 in Patients With Advanced Solid Tumors\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ba1302#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06596915
URL:https://assetmemo.bio/drug/ba1302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
